Brief: Medipal Holdings Announces European Commission Granted Orphan Drug Designation To JR-446
24/06/2025 20:40
June 24 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T: MEDIPAL HOLDINGS : ANNOUNCED EUROPEAN COMMISSION GRANTED ORPHAN DRUG DESIGNATION TO JR-446 Source text: ID:nBw4RVq6Ha Further company coverage: 4552.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results